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Abstract
Background:  RNA interference is a gene regulatory mechanism that employs small RNA
molecules such as microRNA. Previous work has shown that HIV-1 produces TAR viral
microRNA. Here we describe the effects of the HIV-1 TAR derived microRNA on cellular gene
expression.
Results: Using a variation of standard techniques we have cloned and sequenced both the 5' and
3' arms of the TAR miRNA. We show that expression of the TAR microRNA protects infected
cells from apoptosis and acts by down-regulating cellular genes involved in apoptosis. Specifically,
the microRNA down-regulates ERCC1 and IER3, protecting the cell from apoptosis. Comparison
to our cloned sequence reveals possible target sites for the TAR miRNA as well.
Conclusion: The TAR microRNA is expressed in all stages of the viral life cycle, can be detected
in latently infected cells, and represents a mechanism wherein the virus extends the life of the
infected cell for the purpose of increasing viral replication.
Background
RNA interference (RNAi) is a regulatory mechanism con-
served in higher eukaryotes. RNAi functions through the
ability of a small RNA molecule to guide a protein effecter
complex to a complementary sequence of nucleic acid [1-
3]. The end result is the down regulation of protein
expression through either transcriptional silencing, cleav-
age of target mRNA or inhibition of translation. A key
point in understanding RNAi function is the knowledge
that a single microRNA (miRNA) may regulate the expres-
sion of multiple proteins [2,4]. miRNA is produced from
genomic DNA that is transcribed by Pol II in the same
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manner as mRNA. Hairpin secondary structures in this
RNA are recognized and cleaved sequentially by the
actions of the Drosha and Dicer enzymes. The resulting
miRNA is a duplex of two RNA strands approximately 22
nucleotides in length with a two nucleotide 3' overhang
on each strand [4-6]. Ongoing research has revealed that
many viruses, including Human Cytomegalovirus,
Human Herpesvirus 8, Epstein Barr virus, and Simian
Virus 40, express viral miRNA [7-9]. The functions of a
limited number of viral miRNA have been determined
and they appear capable of regulating both viral and cel-
lular gene expression [9-11].
Human immunodeficiency virus type 1 (HIV-1) is the
causative agent of Acquired Immunodeficiency Syndrome
(AIDS) [12,13]. Current therapies are capable of control-
ling viral infection but do not represent a definitive cure.
The HIV-1 virus has proven to be capable of developing
resistance to therapy, evading the immune response, alter-
ing cellular immune function and protecting an infected
cell from apoptosis. The virus must accomplish these
functions with a limited genome that expresses only nine
proteins. As such, the HIV-1 virus must make extensive
use of cellular pathways and subvert native molecular
processes for its own purpose. Therefore, the inclusion of
a miRNA in the viral genome would be a powerful tool for
manipulating cellular function [10,14].
We have previously demonstrated the existence of an HIV-
1 miRNA derived from the RNA hairpin structure at the 5'
end of all HIV-1 transcripts known as TAR [15]. The pro-
teins involved in miRNA biogenesis have been shown to
bind to the TAR element and cleavage of TAR by the cellu-
lar Dicer enzyme results in the production of a ~22 nucle-
otide miRNA. This viral miRNA is detectable in infected
cell lines, in de novo infected primary T-cell blasts, and is
detectable throughout the viral life cycle [15]. Previous
analyses indicate that this miRNA is functional and may
be involved in the regulation of the viral life cycle through
suppression of viral transcription. Recently, an independ-
ent group has confirmed our findings [16]. At least one
paper also suggests that miRNA may be derived from the
HIV-2 TAR element, when the HIV-2 TAR is folded in an
alternate manner [17]. Here we present the sequence of
the HIV-1 TAR miRNA as determined by cloning and
show evidence that HIV-1 TAR miRNA alters the expres-
sion of a number of important cellular genes. In addition,
we show that the outcome of viral miRNA expression is
the protection of the infected cell from apoptosis and
stress induced cell death.
Methods
Cloning and sequencing of the TAR miRNA
cMagi cells were infected with HIVIIIB  and microRNA
enriched libraries were prepared as described using suita-
ble adaptors [18,19]. RT-PCR amplification with an excess
of the reverse primer (1:50 ratio) was employed to pro-
duce a cDNA library. Biotinylated capture oligonucle-
otides were then hybridized to an aliquot (5 ul) of the
library in TEN buffer. (CTCTCTGGCTAACTAGGGAAC-
CCACTG and ACTGGGTCTCTCTGGTTAGACCA-
GATTTGA for HIV-mir-3p and HIV-mir-5p respectively)
Hybridized pairs were captured by uMACS Streptavidin
Kit and the single-stranded miRNA eluted by adding 150
ul of water preheated to 80°C. Recovered single-stranded
cDNA molecules were amplified by PCR, ligated into the
pTZ57R/T vector and transformed into JM109 bacteria.
Positive colonies were identified and sequenced.
siRNA and RNA molecules
TAR-WT and TAR-D were transcribed from previously
described T7 expression vectors [20]. For in vitro transcrip-
tion reactions 1.5 μg of each plasmid was linearized with
HindIII (New England Biolabs), ethanol precipitated and
used for in vitro transcription via the MegaScript High
Yield Transcription Kit (Ambion). After transcription TAR
RNA was purified on a 2% agarose gel, eluted from the gel
with 0.5 M NaAcetate, 1 mM EDTA, 0.2% SDS, and etha-
nol precipitated before re-suspension in DEPC treated
water. siDicer, siLuc, siEGFP and siERCC1 were obtained
from a commercial source (Dharmacon). Transfections
were performed with Metafectene reagent (Biontex).
Cells, cell culture and transfections
293T, cMagi, HeLaT4, HLM-1, CEM, ACH2, U1 and U937
cell lines were obtained from the AIDS Reagent program.
Adherent cells were cultured in DMEM supplemented
with L-glutamine and Pennicilin/Streptomycin with 10%
FBS. Suspension cultures were maintained in RPMI-1640
with L-glutamine and Pennicilin/Streptomycin with 10%
FBS. For serum starvation experiments, media with 0.1%
FBS was used. For transfections, 293T cells were seeded in
a 6 well culture plate at 150,000 cells/well. The following
day the cells were transfected with 500 ng of the appropri-
ate siRNA or TAR RNA using Metafectene (Biontex) lipid
reagent.
Cell cycle analysis and apoptosis
Cells were washed with PBS and fixed with 70% ethanol.
Following rehydration in PBS, cells were stained in PBS
containing 25 ug/ml propidium iodide (Sigma), 10 ug/ml
RNase A (Sigma) and 0.1% NP-40. Cells were analyzed on
a BD FacsCalibur flow cytometer. Cell cycle analysis and
measurement of apoptosis was performed using ModFit
LT software. Aggregates and debris were excluded by gat-
ing on the FL2W and FL2A parameters. Apoptosis was
considered to be the population of cells that were sub-G1.
Apoptosis analyses were confirmed with BD Biosciences
Annexin V Apoptosis detection kit following the proce-
dure outlined by the company.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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Antibodies and Western blots
Dicer antibody was from AbCam. B-actin, Caspase 3,
ERCC1, PIASγ, GIT2, p21/waf1 and MDM2 antibodies
were from Santa Cruz Biotech. P53 pSer 15 antibody was
from cell signaling technologies. Anti-IER3 antibody was
a generous gift from Dr. Francoise Porteu, The Cochin
Institute, Paris, France. Cell extracts were resolved by SDS-
PAGE on a 4–20% tris-glycine gel (Invitrogen). Proteins
were transferred to Immobilon membranes (Millipore) at
200 mA for 2 hours. Membranes were blocked with PBS
0.1% Tween-20 + 5% BSA. Primary antibody against
either Dicer (AbCam, AB14601) or Actin (SantaCruz, SC-
1615) was incubated with the membrane in PBS +0.1%
Tween-20 at 0.5 ug/ml overnight at 4°C. Membranes were
washed three times with PBS +0.1% Tween-20 and incu-
bated with HRP-conjugated secondary antibody for one
hour. Presence of secondary antibody was detected by
SuperSignal West Dura Extended Duration Substrate
(Pierce). Luminescence was visualized on a Kodak 1D
image station.
Affymetrix MicroArray analysis
RNA samples were submitted to the McCormick Genom-
ics center at the George Washington University Medical
for analysis using the Affymetrix Human Focus Array and
standard staining and detection procedures. For microar-
ray analysis 293T cells were transfected in triplicate with
either TAR-WT, TAR-D or siEGFP. After GC-RMA and nor-
malization TAR-WT experimental values were evaluated
as compared to both TAR-D and siEGFP controls. Analysis
of variance was performed with a cutoff p-value of 0.05.
Expression changes were filtered on a fold change of 1.1
and then grouped according to down or up-regulation.
The final list of differentially regulated genes was gener-
ated by selecting genes that were similarly regulated in
both controls as compared to the TAR-WT experimental
transfection (Additional file 1, Figure S1 ).
RT-PCR
RNA samples were prepared using Trizol reagent (Invitro-
gen). cDNA was generated using the iScript Select cDNA
Synthesis kit (BioRad) according to the manufacturers
instructions. Primers used for PCR were: ERCC1F:
GGCGACGTAATTCCCGACTA, ERCC1R: AGTTCTTC-
CCCAGGCTCTGC, IER3F: TCTACCCTCGAGTGGTGAG-
TATC, IER3R: ACTAAGGGGAGACAAAACAGGAG
Results and discussion
Sequencing of the HIV-1 TAR derived miRNA
cMagi cells were infected with HIVIIIB and used to prepare
microRNA enriched libraries [18,19]. HIV-1 TAR miRNA
sequence was then enriched by capture with a bioti-
nylated oligonucleotide. Recovered miRNA library mole-
cules were PCR amplified and cloned into pTZ57R/T
vector and sequenced (Fig. 1A and 1B). Cloning analysis
recovered three clones of the 5' arm of the TAR miRNA
(TAR-5p) and 14 clones of the 3' arm (TAR-3p). The 5' end
of the TAR-5p miRNA appears to be defined by transcrip-
tion start. This and an examination of the 3' miRNA sug-
gest that Dicer acts directly on a short TAR containing
hairpin, possibly without any previous Drosha process-
ing. Drosha processing could occur prior to Dicer cleavage
and serve to generate the Dicer substrate by freeing the
TAR element from a longer RNA. Potential Drosha cleav-
age may account for the existence of clones starting one
base after transcription start (the second G). Comparison
to the predicted sequence in the Sanger miRNA database
(from Ouellet et al.) showed that these cloned sequences
differ from previous expectations [16].
TAR miRNA has an anti-apoptotic effect
We sought to identify a phenotype associated with the
TAR miRNA by examining broad effects on the cell cycle.
In order to identify the effects of the TAR miRNA specifi-
cally, rather than HIV infection in general, we began our
investigations by studying 293T cells that were transfected
with the TAR RNA. In the first experiment, 293Ts were
transfected with either the wild-type TAR RNA (TAR-WT)
or with a truncated mutant TAR RNA (TAR-D) (Fig. 1C).
Following transfection, RNA extracts were prepared and
Northern blotted to confirm the presence of mature TAR
miRNA in TAR-WT, but not TAR-D, containing cells (Fig.
1D). Transfected cells were then plated with low-serum
media (0.1% FBS DMEM) and harvested after 48 hours.
The cells were fixed and stained with Propidium Iodide
(PI) and the populations were analyzed by flow cytome-
try.
The flow cytometric breakdown indicated that the TAR
miRNA had an effect on cell-cycle and survival when
under stress. Serum starvation of TAR-D transfected cells
led to an arrest in the G1 phase of the cell cycle by 24
hours (86.8% as compared to 46.7% in the cells with full
serum). By 48 hours, nearly all the cells were in a sub-G1
peak indicative of possible apoptosis. Whereas the cells
without the miRNA showed high levels of apoptosis after
48 hours of serum starvation (70%), the 293T cells with
the TAR miRNA showed alterations in cell cycle but were
not nearly as apoptotic (no significant change in apopto-
sis after 48 hours) (Fig. 2A). Interestingly, the TAR-WT
containing cells not only survived, but continued to
progress through the cell cycle as evidenced by the pres-
ence of cells in the S and G2/M phases. Although at 24
hours of serum starvation TAR-WT containing cells did
start to accumulate in the G1 phase (66.6% as compared
to 44.3%) this did not lead to cell death, and at 48 hours
cells were observable in all phases of the cell cycle. The
increase in cells in the S-phase as compared to cells with
serum suggests that the cells are replicating more slowly.
Indeed, TAR-WT transfected cells appear to have a greaterRetrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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portion of cells in the S phase than the control cells even
in full serum (compare untreated TAR-D to TAR-WT). The
induction of apoptosis was verified using Annexin V stain-
ing (2B). HeLa cells were transfected with TAR-D or TAR-
WT RNA and serum starved for 96 hours. The increase in
Annexin V positive, PI negative cells after serum starvation
of the TAR-D transfected cells indicates apoptosis (2.0%
to 9.9%). Apoptosis in serum starved, TAR-WT treated
HeLa cells was not as high (4.5%). These results suggest
that the TAR miRNA is able to decrease levels of apoptosis
in stressed cells. To investigate this phenotype in another
stress-context, we again used 293T cells transfected with
either the TAR-D or TAR-WT, but this time we treated the
cells with the DNA crosslinking agent Mitomycin C. Upon
analysis by flow cytometry, we observed the same trend as
when the cells were deprived of serum; the cells contain-
ing the miRNA were more resistant to apoptosis (No
increase in the level of apoptosis) compared to the control
transfection (TAR-D containing cells experienced over 40
fold increase in apoptosis) (Data not shown). These data
indicate that the TAR miRNA has the ability to protect
cells from stress-induced cell death.
Anti-apoptotic effect in infection
After observing the role of the TAR miRNA in protecting
the cells from apoptosis under stress, we decided to inves-
tigate whether the miRNA had similar effects in chroni-
cally infected cell lines. We compared the effects of
Determination of the sequence of that HIV-1 TAR miRNA Figure 1
Determination of the sequence of that HIV-1 TAR miRNA. RNA from cMagi cells infected with HIVIIIB was used to 
construct miRNA libraries and used for cloning. (A) Cloned sequences of the TAR-5p and TAR-3p (5' and 3' arm) miRNA 
obtained as compared to predicted sequence registered with the Sanger miRNA database. (B) Diagram showing the TAR hair-
pin and the position of the mature miRNA within the TAR sequence. (C) Structure of the TAR-WT and truncated TAR-D 
mutant used for 293T transfections. (D) 293T cells were mock transfected (lane 2) or transfected with TAR-WT (lane 3) or 
TAR-D (lane 4) RNA. Forty-eight hours after transfection RNA was isolated and subjected to Northern blotting for TAR 
sequence. Numbers to the left indicate the size of the RNA ladder in nucleotides. Diagrams to the right show the positions of 
the wild-type TAR and the mature TAR miRNA.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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induced stress on two infected cell lines, HLM1 (HIV-1
infected cervical epithelial carcinoma cell line) and ACH-
2 (HIV-1 infected CD4+ T-cell line) to the effects on their
uninfected counterparts, HeLa T4 and CEM, respectively.
We selected the HLM1 and ACH-2 cell lines as they have
often been used as models for viral latency and can be
induced to express high levels of viral protein with various
agents. We have previously shown that both of these cell
lines express the TAR miRNA, by means of an RNase Pro-
tection Assay (RPA) with a radiolabeled TAR RNA probe
[15]. The four cell lines were plated with 0.1% FBS, and
collected daily for four consecutive days. We performed a
flow cytometry analysis of the AnnexinV/PI-stained cells
in order to determine the possible effects of the TAR
miRNA on apoptosis in vivo.
According to the FACs analysis, the uninfected HeLa T4s
began to apoptose at 48 hours of serum starvation and
this continued through 96 hours. The HeLa T4s showed
about 16% apoptosis after 96 hours (as compared to only
2.0% in the presence of serum), the HLM1s experienced
virtually no increase in the level of apoptosis at the same
time point (compare Fig. 3B to 3D). The percentage of PI/
AnnexinV double positive cells also increased in the
Transfection of TAR miRNA into 293T cells has an anti-apoptotic effect Figure 2
Transfection of TAR miRNA into 293T cells has an anti-apoptotic effect. (A) 293T cells were transfected with TAR-
D control or TAR-WT RNA. Twenty-four hours post transfection the media was replaced with DMEM with 0.1% FBS. Cells 
were sampled at Zero and 48 hours post serum starvation, stained for cell cycle analysis using propidium iodide (PI), and ana-
lyzed by flow cytometry. (B) HeLaT4 cells were transfected TAR-D or TAR-WT RNA. Twenty-four hours post transfection 
the media was replaced with DMEM with 0.1% FBS. Cells were sampled at 96 hours, and apoptosis was determined via Annex-
inV and PI co-staining. Data are representative of three experiments.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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serum-starved HeLaT4 cells and not in the HLM1, suggest-
ing an overall increase in cell death associated with apop-
tosis.
Like the HLM-1s, the HIV-1 infected ACH-2 cells exhib-
ited a resistance to serum starvation induced apoptosis.
When stressed, the levels of apoptosis in ACH-2 cells
increased less than in their uninfected control (CEM).
According to the flow cytometry analysis of the cell popu-
lations, after 96 hours of serum starvation the CEM cells
increased in their apoptotic level by 30% whereas the
ACH-2 cells increased in apoptosis by only 10% (Fig 4
compare panel B to A and C to D).
To confirm this phenotype at the protein level, we West-
ern blotted the extracts from the various cell lines for Cas-
pase 3. The results indicated that at 48 hours of serum
starvation, Caspase 3 was cleaved at higher levels in HeLa
T4 cells (78% cleavage) than in the HLM1 equivalents
(56% cleavage). (Fig. 5A lanes 3 and 4). The increased
apoptosis seen at 72 hours is supported by the preceding
cleavage of Caspase 3 at 48 hours. Western blotting for
Caspase 3 also confirmed that CEM cells are apoptosing at
higher levels (25% cleavage) than the ACH-2 cells (14%
cleavage) (Fig. 5B, compare lanes 3 and 4). These data
indicated that HIV-1 infected cells, which produced
detectable levels of the TAR miRNA in vivo (and in the case
HIV-1 infected cell lines are resistant to apoptosis Figure 3
HIV-1 infected cell lines are resistant to apoptosis. HelaT4 (A, B) and HLM-1 (C, D) were cultured in the presence of 
10% serum (A, C) or 0.1% serum (B, D) for 96 hours. Cells were then collected and apoptosis determined via AnnexinV and 
PI co-staining. Data are representative of three experiments.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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of HLM-1 and ACH-2 produced little to no full length
viral mRNA), were capable of withstanding stress-induced
apoptosis. The lack of viral protein expression in these
cells suggested that this phenotype was due to the viral
miRNA processed from short, abortive viral RNA tran-
scripts [21].
Anti-apoptotic effect is Dicer dependent and can be 
reversed by blocking miRNA function
As HIV-1 infection or transfection with an RNA may have
a broad effect on the cell, we sought to confirm that the
anti-apoptotic effect is specific to the TAR miRNA. To test
this hypothesis we employed an antagomir, with
sequence complementary to the mature miRNA, to pre-
vent the miRNA from functioning. HeLaT4 or HLM-1 cells
were transfected with antagomir or were mock trans-
fected. Twenty-four hours after transfection the cells were
transferred to low-serum media and grown for 96 hours.
Cells were then harvested and apoptosis was determined
by AnnexinV/PI staining followed by flow cytometry (Fig.
6). Treatment of the HeLaT4 or HLM-1 cells with antago-
mir caused no change in apoptosis or cell-cycle progres-
sion in the absence of serum starvation (data not shown).
HLM-1 cells subjected to mock transfection were still
resistant to apoptosis, as we had previously seen (Fig. 6A).
However, HLM-1 cells treated with the antagomir showed
a level of apoptosis equal to that seen in the HeLa cells
(Fig. 6B). The anti-apoptotic effect can be blocked by
employing an antagomir specific to the sequence of the
TAR miRNA, suggesting that the effect is specific to the
miRNA.
Infected T-cell lines are resistant to apoptosis Figure 4
Infected T-cell lines are resistant to apoptosis. CEM (A, B) and ACH2 (C, D) were cultured in the presence of 10% 
serum (A, C) or 0.1% serum (B, D) for 96 hours. Cells were then collected and apoptosis determined via AnnexinV and PI 
co-staining. Data are representative of three experiments.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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Serum starvation induced cleavage of Caspase 3 in uninfected but not infected cells Figure 5
Serum starvation induced cleavage of Caspase 3 in uninfected but not infected cells. (A) HeLaT4 (lanes 1 and 3) 
and HLM-1 (lanes 2 and 4) were Western blotted for Caspase 3 expression and cleavage at Zero (lanes 1 and 2) and 48 (lanes 
3 and 4) hours after serum starvation. (B) CEM (lanes 1 and 3) and ACH2 (lanes 2 and 4) were Western blotted for Caspase 
3 expression and cleavage at Zero (lanes 1 and 2) and 48 (lanes 3 and 4) hours after serum starvation. Densitometry was per-
formed to determine the density of the cleaved 17 and 20 kDa Caspase 3 bands as compared to the 32 kDa inactive form.
Specifically blocking TAR miRNA sensitized cells to apoptosis Figure 6
Specifically blocking TAR miRNA sensitized cells to apoptosis. HLM-1 cells were transfected with antagomir comple-
mentary to the TAR 5' miRNA. Twenty-four hours post transfection the media was replaced with DMEM with 0.1% FBS. Cells 
were sampled at 96 hours and apoptosis determined via AnnexinV and PI co-staining. Percentages shown indicate the number 
of AnnexinV positive, PI negative and AnnexinV, PI double positive cells.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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To confirm that the anti-apoptotic phenotype is due to
miRNA production, and not other viral factors, we
knocked down Dicer expression in the HIV-1 infected
cells. HLM-1 or HeLa control cells were transfected with
siRNA against Dicer (siDicer) or control siRNA (siLuc).
Twenty-four hours after transfection the cells were serum
starved. At baseline, all four conditions showed compara-
ble levels of apoptosis. At 96 hours of serum starvation,
the control HeLa cells showed similar levels of apoptosis
regardless of which siRNA was used. However, HLM-1
cells transfected with siDicer showed a level of apoptosis
higher than that detected in the HeLa cells (50%) (data
not shown). This indicated that resistance to apoptosis
was dependent upon the expression of the Dicer protein.
As Dicer is required to process the TAR hairpin into a func-
tional miRNA, these results suggest that resistance to
apoptosis is mediated by the TAR viral miRNA.
TAR miRNA alters apoptotic genes
The observation that the HIV-1 TAR miRNA is expressed
both in latent and in active infection suggests that the
miRNA may play a role in regulating cellular gene expres-
sion [15]. We reasoned that expression of the miRNA at all
points during infection may have a broad pro-viral effect
such as immune evasion, cell survival, or increased viral
production. To test this hypothesis, 293T cells were trans-
fected with the TAR-WT (which we have previously shown
to be processed into the viral miRNA [15] and Fig. 1D),
TAR-D, or a control siRNA (siEGFP) (Fig. 1C).
RNA from the transfection was used for microarray analy-
sis employing an Affymetrix Human Focus Array. Changes
in gene expression were considered valid if they occurred
in the TAR transfection as compared to both controls, had
a P-value of less than 0.05, and the levels of detection
changed by more than 10% (Fig S1). This analysis indi-
cated that 32 genes were significantly altered by the pres-
ence of the HIV-1 miRNA (18 down-regulated, 14 up-
regulated). As the primary function of RNAi is to silence
gene expression, we postulated that the up-regulated
genes may be a secondary effect related to repression of a
regulatory gene. After examining the down-regulated
genes we identified many potentially interesting targets
related to replication, receptor signaling, DNA repair,
mitochondrial function and apoptosis. In order to deter-
mine which of these pathways was truly regulated by the
viral miRNA we sought to determine which genes may be
related to the observed phenotype.
In examining the potential list of HIV-1 miRNA regulated
genes, we selected four genes with possible links to apop-
tosis and cell survival for further study; ERCC1, PIASγ,
GIT2 and IER3. Excision repair cross complementing-
group 1 (ERCC1) is involved in the detection and base
excision repair of damaged nucleotides [22]. Protein
inhibitor of activated STAT Y (PIASγ) is an inhibitor of
STAT1 signaling, and is capable of modulating NFκB sig-
naling, and also functions as a transcriptional co-repressor
due to E3 Sumo ligase activity [23,24]. G protein-coupled
receptor interacting protein (GIT2) is involved in G-pro-
tein signaling [25]. Intermediate early response 3 (IER3) is
up-regulated after cellular insult and has been shown to
be required for induction of apoptosis after serum starva-
tion and DNA damage [26-29]. We tested the ability of the
TAR miRNA to down-regulate these four genes using
Western blotting (Fig. 7A). 293T cells were transfected
with TAR-WT, TAR-D or were mock transfected. Forty-
eight hours after transfection, cell extracts were prepared,
and protein expression was examined by Western blot-
ting. While there was no change in the expression level
between mock and TAR-D transfections, ERCC1, PIASγ,
GIT2 and IER3 were all down-regulated in the presence of
TAR-WT when normalized to actin.
To confirm that these proteins were differentially regu-
lated in infected cells, Western blottings were performed
on the infected cell pairs: HeLa/HLM-1, CEM/ACH2 and
U1/U937 (Fig. 7B). Expression was quantified as the ratio
of protein levels in HLM-1, ACH2 and U1 as compared to
their uninfected control. U1 and U937 were included as
controls in this experiment because U937 cells do not
express Dicer [15] and hence they should not show differ-
ential expression of the target genes. All four genes of
interest were down-regulated in HLM-1 as compared to
HeLa (ranging from 30–60% decrease). GIT2 and IER3
were down-regulated in ACH2 as compared to CEM,
while ERCC1 and PIASγ were not significantly changed.
PIASγ expression was also not altered in U1 as compared
to U937. Interestingly, the expression levels of ERCC1,
GIT2 and IER3 were increased in U1 as compared to the
uninfected U937 cells. This indicated that the viral infec-
tion may be up-regulating expression of these proteins,
and the viral miRNA was serving to counteract this effect.
Collectively, these experiments indicated that HIV-1
miRNA down-regulated ERCC1, GIT2 and IER3.
To verify that repression of ERCC1 in the infected cells
was due specifically to the action of the miRNA, and not
other viral factors, we again employed the antagomir spe-
cific for the TAR 5' miRNA (Fig. 7C). HLM-1 cells were
transfected with TAR 5' antagomir or were mock trans-
fected. Four days after transfection the cells were collected,
lysed, and proteins were separated by SDS-PAGE and
Western blotted for ERCC1. Transfection of the antagomir
increased the level of detectable ERCC1 in HLM-1 cells.
ERCC1 was upregulated by viral infection in the absence
of Dicer by 18 fold (Fig. 5B). This is in keeping with pub-
lished reports that viral infections, including HIV-1, up-
regulate the expression of DNA repair proteins. ERCC1 isRetrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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involved in the recognition and repair of DNA damage.
Indeed, previously published reports indicate that
increased levels of ERCC1 correlate with resistance to
DNA damage induced apoptosis [30-32]. Our findings
suggest a novel role for ERCC1 in inducing apoptosis in
response to serum starvation. To confirm the role of
ERCC1 in protection from serum starvation induced
apoptosis, siRNA was utilized. 293T cells were transfected
with TAR-D, TAR-WT or siRNA against EGFP or ERCC1.
Cells were serum starved for 48 hours, and the level of
apoptosis was determined at 96 hours post serum starva-
tion (Fig. 8A). Control transfection of TAR-D showed that
9.9% of the cells were apoptotic. siRNA against ERCC1
prevented the induction of apoptosis at 48 hours, compa-
rable to the transfection with wild type TAR RNA. Trans-
fection of 293T cells and cell cycle analysis confirmed
these results (data not shown). These results suggested
that in the setting of 293T cells, repression of ERCC1
expression inhibited apoptosis triggered by serum starva-
tion. IER3 has previously been shown to be involved also
in serum starvation induced apoptosis [26-29]. Together
these data suggested that the TAR miRNA prevented apop-
tosis by down-regulating both ERCC1 and IER3.
Induction of apoptosis via serum starvation is mediated
by p53. Activation of p53 induces the expression of
Mdm2, p21/waf1 and Bax [33]. Bax is trans-located to the
mitochondria and begins the apoptotic cascade [34].
Mdm2 and p21/waf1 serve to regulate the cell cycle and
feed back on p53 [33,35]. We sought to confirm the
involvement of ERCC1 repression by the TAR miRNA in
p53 mediated apoptosis by following the activation state
of p53 and the expression of Mdm2 and p21/waf1 (Fig.
8B). 293T cells were mock transfected or transfected with
HIV-1 miRNA down-regulated the expression of proteins related to apoptosis Figure 7
HIV-1 miRNA down-regulated the expression of proteins related to apoptosis. (A) 293T cells were mock trans-
fected (lane 1) or transfected with TAR-D mutant (lane 2) or TAR-WT RNA (lane 3). After 48 hours cell lysates were pre-
pared and Western blotted for ERCC1, PIASγ, GIT2, IER3 or β-actin. (B) Cell lysates were prepared from HeLaT4, HLM-1, 
CEM, ACH2, U1 and U937 cell lines and Western blotted for ERCC1, PIASγ, GIT2, IER3 or β-actin. Densitometry was per-
formed, and the expression levels were normalized to actin. The average expression level of each protein from three experi-
ments was determined and displayed as the ratio of expression in the infected cells (HLM-1, ACH2 and U937) to their 
uninfected counterpart (HeLaT4, CEM, U1). (C) HLM-1 cells were transfected with mock (lane 1) or TAR 5' antagomir (lane 
2). Cells were lysed after 96 hours and 20 micrograms of protein were used to Western blot for the expression of ERCC1. 
Coomassie staining of the ~25–50 kDa portion of the gel is included as a loading control.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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siRNA against ERCC1. Twenty-four hours after transfec-
tion the cells were cultured in 0.1% FBS for 0, 4, 8 and 24
hours. Cell extracts were prepared at each time point and
Western blotted for p53 phosphorylated on serine 15
(p53 PS15), Mdm2, p21/waf1 and β-actin. Serum starva-
tion of the control cells triggered an increase in p53 phos-
phorylation and a subsequent increase in the expression
of Mdm2 and p21/waf1 (Fig. 8B, lanes 1–4). The phos-
phorylation of p53 was highest at the 24 hour time point,
but increased phosphorylation can be seen from 4 hours
on. Interestingly, 293 cells transfected with the siRNA
against ERCC1 showed only a small increase in p53 phos-
phorylation that peaked at 8 hours (Fig. 8B lane 7), a
slight increase in Mdm2 at 8 hours and no increase in p21
expression (lanes 5–8). Furthermore, the levels of p53
phsophorylation, Mdm2 and p21 in the ERCC1 knock-
down before serum starvation all appeared lower than in
the control cells (compare lane 1 to lane 5). Transfection
of TAR-WT RNA showed a similar phenotype as the
ERCC1 knockdown (data not shown). These results indi-
cated a new role for ERCC1 in influencing the activation
of p53 in response to cellular stress.
Repression of gene expression by RNAi requires sequence
homology between the target and the miRNA. We ana-
lyzed ERCC1 and IER3 mRNA sequences for the presence
of sequences complementary to the HIV-1 viral miRNA
using the search algorithm miRanda (Fig. 9A) [36]. Statis-
tical analysis was performed to eliminate matches due to
random chance. Six potential target sequences were iden-
tified within the ERCC1 mRNA and five within the IER3
mRNA. Analysis also indicated that each of the genes
listed in Table 1 as being down-regulated, with the excep-
tion of TIMM, have multiple target sites for the viral
Anti-apoptotic effect validated through the repression of ERCC1 Figure 8
Anti-apoptotic effect validated through the repression of ERCC1. (A) HeLaT4 were transfected with TAR-D, TAR-
WT, siEGFP, or siERCC1 RNA. Twenty-four hours after transfection media were replaced with low serum (0.1%) media, and 
the cells were cultured for 96 hours. Apoptosis was measured at 96 hours after serum starvation using FACs analysis. Data are 
representative of two experiments. (B) 293T cells were transfected with siRNA against ERCC1 (lanes 5–8) or mock (lanes 1–
4) for twenty-four hours, and then the media was replaced with low serum media. Cells were harvested for Western blot anal-
ysis at 0, 4, 8 and 24 hours after serum starvation and Western blotted for phosphor-p53 Ser15, Mdm2, p21 and β-actin. Pic-
tured Western blots utilized 20 micrograms of total protein per lane.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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miRNA. Interestingly, multiple target sites for the TAR 5'
miRNA were found in 17 of the 18 down-regulated genes
(Additional file 2, Supplemental file 2). However, the TAR
3' miRNA had only single possible targets in a small
number of genes (Additional file 3, Supplemental file 3).
This suggests that the TAR 5' miRNA is more likely the
functional RNA strand.
To confirm that TAR derived miRNA can target the ERCC1
gene we cloned a cluster of the potential target sites into
the psiCheck reporter construct (Invitrogen) (Fig. 9B). psi-
Check contains a Renilla luciferase reporter with a multi-
ple cloning site in the 3'UTR for the insertion of potential
miRNA target sites, and a firefly luciferase reporter for nor-
malization. A region of the ERCC1 gene containing three
TAR 5' miRNA targeted the ERCC1 gene directly Figure 9
TAR 5' miRNA targeted the ERCC1 gene directly. (A) miRanda software was used to determine potential target sites 
in the ERCC1 and IER3 mRNA sequences for the HIV-1 TAR 5' miRNA. (B) 293T cells were transfected with TAR-D or TAR-
WT RNA. Twenty-four hours after RNA transfection the cells were transfected with psiCheckERCC-737 reporter vector. 
Extracts were prepared and luciferase expression determined at 24, 48 and 72 hours after reporter transfection. Data shown 
represent the normalized expression of Renilla luciferase (with the target region) to firely luciferase. Data are representative of 
two replicates.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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potential target sites (bp 737–945) was PCR amplified
and inserted into the psiCheck vector to form psiCheck-
ERCC-737. 293T cells were transfected with either TAR-D
or TAR-WT RNA. Twenty-four hours after transfection of
RNA the psiCheckERCC-737 vector was transfected into
the cells. Cell extract was prepared at 24, 48 and 72 hours
after transfection. Luciferase expression was determined,
and the expression of the target site containing Renilla
luciferase was normalized to the firefly luciferase. No
expression of Renilla luciferase was detected on day one or
two. However, at 72 hours, robust luciferase expression
was detectable in the TAR-D containing cells and not the
TAR-WT cells (Fig. 9B). Neither TAR-D nor TAR-WT had
any effect on the expression of a reporter not containing
the target sequence (data not shown).
TAR miRNA altered the protein expression without 
affecting the mRNA
Our results indicated that the TAR 5' miRNA repressed
ERCC1 expression and cellular apoptosis. Presumably this
effect is through the miRNA pathway; perhaps through
the silencing of translation by recruitment of the mRNA to
the P-body. To confirm this assumption, we sought to
examine the level of mRNA expression of ERCC1 and
IER3 in the presence and absence of the TAR miRNA. To
further control for a miRNA effect, we sought to utilize a
control that still produces a mature miRNA, but has a
mutated seed sequence. We used a pair of Pol III expres-
sion vectors that express either a WT TAR or a TAR element
with a scrambled sequence in the stem corresponding to
positions 6–16 of TAR and the complementary based on
the 3' side of the stem (Generous gift of Dr. Rossi, City of
Hope, CA). Both the pPol III-TAR and pPol III-Scr vectors
produce a mature miRNA (Rossi and Castanotto, unpub-
lished data). To verify that Pol III-TAR produces a miRNA
that can affect ERCC1, we again performed the luciferase
reporter assay using the psiCheck and psiCheckERCC-737
vectors (Fig. 10A). 293T were transfected with psiCheck or
psiCheckERCC-737 and pPol III-Scr or pPol III-TAR vec-
tors, and luciferase expression was measured 72 hours
later. Renilla expression was normalized to an internal
control firefly luciferase. The data indicated that pPol III-
TAR vector suppressed the expression of the luciferase
mRNA containing the miRNA target sequence. This effect
was not seen with a control vector (data not shown).
We next sought to examine the ability of pPol III-TAR to
effect ERCC1 protein expression and mRNA levels. 293T
cells were transfected with pPol III-TAR or pPol III-Scr.
Forty-eight hours after transfection cells were harvested
and protein and RNA extracts prepared. Protein extracts
were analyzed by Western blotting for the expression of
ERCC1 and β-actin (Fig. 10B). The Western blot analysis
revealed the repression of ERCC1 protein expression by
the pPol III-TAR plasmid, similar to the results seen with
the transfection of the TAR-WT RNA. To confirm that this
repression was due to miRNA and not to any secondary
effect of the procedure, RT-PCR was performed on the
extracted RNA to examine the mRNA levels of ERCC1 and
IER3 (Fig. 10C). PCR results indicated no change in the
levels of mRNA for either gene. RT-PCR on RNA extracts
from 293T cells transfected with TAR-D or TAR-WT RNA
also indicated no change in mRNA level. These results
strongly suggested that the TAR miRNA worked by
repressing the translation of targeted mRNA.
Conclusion
Using a modified version of the standard miRNA sequenc-
ing protocol, we enriched HIV-1 TAR derived miRNA
using biotinylated capture oligonucleotides. This
approach allowed us to successfully obtain the exact
sequence of both strands of the TAR miRNA. Interestingly,
we were able to sequence more clones for the 3' miRNA
(hiv1-miR-TAR-3p) than the 5' miRNA (hiv1-miR-TAR-
5p). However, the identification of target sites in ERCC1
and IER3 revealed a greater number of target sites for the
TAR-5p than the TAR-3p. This trend was also found for the
other genes identified as down-regulated in our microar-
ray experiment (with the exception of Translocase of inner
mitochondria membrane which contains no target
sequences, Supplemental Data). These findings are in
keeping with our previous work, wherein we could detect
the 5' miRNA sequence, but not the 3'sequence in stably
infected cell lines.
The cloning described in this current work revealed a dif-
ferent sequence for the TAR 5' than what has been previ-
ously proposed (Fig. 1A). Our cloning analysis suggested
the existence of a 20 nucleotide product starting from
transcription start site. Previous work by Ouellet et al. pre-
dicted a 24 nucleotide miRNA that starts from +4 after the
transcription start site [16]. The assays presented in our
manuscript lead us to believe that our sequenced clone is
correct. However, we cannot rule out the alternative form
since the important seed sequence for both clones overlap
and may allow them to target similar mRNAs. Further
work must be performed to distinguish which of the two
miRNA RNA is expressed in HIV-1 infected cells and
which is functional.
The HIV-1 TAR miRNA causes cells to become resistant to
apoptosis in the setting of transfection and infection, and
this effect is dependent upon Dicer expression. These data
indicate that the HIV-1 TAR miRNA is capable of down-
regulating cellular gene expression and altering the cellu-
lar phenotype. The viral miRNA is expressed at all stages
of the viral life cycle and thus has implications for HIV-1
infection [15]. Previously, HIV-1 infection has been
shown to alter cellular gene expression [37-39] and cellu-
lar microRNA expression [40-42]. These changes areRetrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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mediated by viral proteins, with a particular emphasis on
Tat, Nef and Vpr. The alteration of cellular gene expression
by viral protein has been linked to evasion of the immune
response (downregulation of MHC by Nef), resistance to
apoptosis (Nef), induction of apoptosis in bystander cells
(Tat and VPR), alterations in cell cycle and replication
(Tat) [39,43-45], and suppression of RNAi silencing (Tat)
[46-48]. All of these changes are meant to increase viral
TAR miRNA altered ERCC1 protein expression without altering mRNA levels Figure 10
TAR miRNA altered ERCC1 protein expression without altering mRNA levels. (A) 293T cells were transfected 
with psiCheckERCC-737 and either pPolIII TAR or pPolIIIScr. Renilla and firefly luciferase expression was measured after 72 
hours. Data shown represent the normalized ratio of Renilla luciferase to firefly luciferase for two replicates. 293T cells were 
transfected with either pPolIII TAR or pPolIIIScr. Forty-eight hours after transfection the cells were harvested and protein and 
RNA extracts were prepared. (B) Protein extracts were Western blotted for ERCC1 and β-actin expression. (C) RNA 
extracts were used to generated cDNA, and ERCC1 and IER3 mRNA levels were determined by PCR.Retrovirology 2009, 6:18 http://www.retrovirology.com/content/6/1/18
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replication and prolong the period of time in which a cell
is capable of producing infectious virus. Our data on the
HIV-1 viral miRNA, however, demonstrates a role for viral
RNA in altering cellular gene expression. These findings
are in keeping with previous reports on alteration of cellu-
lar pathways by the virus, as the miRNA serves to protect
the cells from apoptosis. These data take on even greater
significance due to the fact that the HIV-1 miRNA is
expressed in active and latently infected cells – even in the
absence of viral protein production.
We performed microarray analysis to screen for genes pos-
sibly regulated by the HIV-1 TAR miRNA. Although
miRNA are generally active in the repression of transla-
tion, we took the relatively modest changes in mRNA as a
hallmark of possible silencing of protein translation. To
confirm this hypothesis we examined the expression of
four proteins with possible links to apoptosis; ERCC1,
PIASγ, GIT2 and IER3 [22-26]. Although all four genes
were down-regulated in transfection, only GIT2 and IER3
were reliably down-regulated in HLM-1 and ACH2 as
compared to their control. Interestingly, the levels of the
ERCC-1 protein seem to be drastically up-regulated dur-
ing infection in the absence of functional RNAi. This raises
the possibility that the miRNA may be specifically acting
to prevent changes in gene expression caused by viral
infection. Indeed, preliminary experiments indicate that
the mRNA levels of ERCC1 are elevated in ACH2 cells as
compared to CEM, despite the opposite being true at the
protein level (data not shown and Fig. 7). Although GIT2
has potentially important roles in regulating cell survival,
the silencing of IER3 and ERCC1 are likely the reason for
the anti-apoptotic phenotype we have observed. IER3's
effect on apoptosis has been previously studied. Interest-
ingly, in the setting of serum starvation and DNA damage,
the loss of IER3 expression is anti-apoptotic [27-29]. Our
finding that cells containing the HIV-1 miRNA are pro-
tected from MMC induced apoptosis (Fig. 2) supports a
role for the miRNA in regulating IER3. Further analysis
indicates that in 293T cells the silencing of ERCC1 by
siRNA is sufficient to protect the cells from serum starva-
tion induced apoptosis. Our previous work indicated that
the viral miRNA may also function to regulate viral gene
expression: an effect similar to the miRNA encoded by
SV40 and involved in viral latency [9,15].
We found the presence of multiple validated target sites in
the ORF of the ERCC1 gene intriguing. The generally
accepted rules for miRNA targeting require a rather precise
seed sequence match to an area in the 3'UTR. However, in
this case, the HIV 5' miRNA appears to target a triplex of
sites in the reading frame of the gene. Cloning of this
region into a reporter indicates that it is a functional target
and the presence of three closely located sites also suggests
a bona fide miRNA target. The lack of perfect base-pairing
in the seed sequence is reminiscent of that described for
the let-7:lin-41 interaction, wherein a single base bulge is
tolerated in the miRNA:target pairing [49]. Work on
miRNA targeting suggests that the ability of a miRNA to
successfully repress a target gene is very dependant on the
context of the sequence flanking the target sites [50-52].
Several other examples, including the targeting of Dicer by
let7 and microRNAs regulating Nanog, Oct4 and Sox2,
indicate that microRNAs are capable of down-regulating
genes through targeting of their ORFs [53,54]. One group
even suggests that miRNA can target the 5'UTR [55]. We
believe that this work has uncovered another miRNA
capable of driving down-regulation of a target gene
through interaction with a sequence in the ORF. These
findings serve to indicate that there is still much that we
do not know about how miRNA functions and indicate a
need for ongoing research into how the RISC complex
interacts with target mRNA.
A recent trend in the development of HIV-1 therapeutics
has been to use peptides and small molecules in an
attempt to specifically induce cell death in the HIV
infected cell [56,57]. This approach has become attractive
as it would clear the reservoir of cells producing virus,
including the latent pool [58]. The discovery that infected
cells which are transcriptionally silent may still be resist-
ant to apoptosis due to the presence of TARmiRNA has
clear implications for therapy.
On the basis of these findings, we propose the following
model for the action of HIV-1 TAR miRNA. Basal tran-
scription of the HIV-1 LTR leads to production of short,
TAR containing, RNA hairpin sequences. These hairpins
are acted upon by the proteins involved in miRNA biogen-
esis, specifically Dicer to yield a viral miRNA. This miRNA
is loaded into the RISC complex and regulates the expres-
sion of several cellular genes through inhibition of trans-
lation, leaving mRNA levels un-affected. The net effect of
this interference is that the infected cell becomes resistant
to apoptosis. Previous studies on the IER3 gene suggest
that it may be involved, but our analysis indicates that
another major target of the HIV-1 viral miRNA may be the
ERCC1 gene.
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